SANDOZ FINGOLIMOD CAPSULE
Nchi: Kanada
Lugha: Kiingereza
Chanzo: Health Canada
Tabia za bidhaa
(SPC)
23-02-2022
Hati zingine za bidhaa hii hazipatikani kwa sasa, unaweza kutuma ombi kwa huduma ya wateja wetu na tutakuarifu mara tu tutakapopata.
Tuma ombi.
Tuma ombi.
Viambatanisho vya kazi:
FINGOLIMOD (FINGOLIMOD HYDROCHLORIDE)
Inapatikana kutoka:
SANDOZ CANADA INCORPORATED
ATC kanuni:
L04AE01
INN (Jina la Kimataifa):
FINGOLIMOD
Kipimo:
0.5MG
Dawa fomu:
CAPSULE
Tungo:
FINGOLIMOD (FINGOLIMOD HYDROCHLORIDE) 0.5MG
Njia ya uendeshaji:
ORAL
Vitengo katika mfuko:
28
Dawa ya aina:
Prescription
Eneo la matibabu:
Immunomodulatory Agents
Bidhaa muhtasari:
Active ingredient group (AIG) number: 0152886001; AHFS:
Idhini hali ya:
APPROVED
Idhini ya tarehe:
2019-03-11
Tabia za bidhaa
_Sandoz Fingolimod _
_Page 1 of 68 _
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
SANDOZ
® FINGOLIMOD
Fingolimod capsules
Capsule, 0.5 mg fingolimod (as fingolimod hydrochloride), Oral
Sphingosine 1-phosphate receptor modulator
Sandoz Canada Inc.
110, Rue de Lauzon
Boucherville, Québec, Canada
J4B 1E6
Date of Inital Authorization:
October 31, 2019
Date of Revision:
February 23, 2022
Submission Control No: 256559
_Sandoz Fingolimod _
_Page 2 of 68 _
RECENT MAJOR LABEL CHANGES
2 Contraindications
02/2022
4 Dosage and administration
02/2022
7 Warnings and Precautions
02/2022
TABLE OF CONTENTS
RECENT MAJOR LABEL
CHANGES..............................................................................................2
TABLE OF CONTENTS
................................................................................................................2
PART I: HEALTH PROFESSIONAL INFORMATION
.......................................................................4
1
INDICATIONS
................................................................................................................4
1.1
PEDIATRICS
............................................................................................................4
1.2
GERIATRICS
............................................................................................................4
2
CONTRAINDICATIONS ..................................................................................................
4
4
DOSAGE AND ADMINISTRATION
..................................................................................
5
4.1
DOSING
CONSIDERATIONS.........................................................................................5
4.2
RECOMMENDED DOSE AND DOSAGE ADJUSTMENT
.....................................................7
4.4
ADMINISTRATION
....................................................................................................8
4.5
MISSED
DOSE.......................................................................................................
Soma hati kamili
